Physostigmine results in an increased decrement in brain glucose consumption in Alzheimer's disease

Psychopharmacology

Volumn 136, Issue 3, 1998, Pages 256-263

  Blin, Jerome ^a,b,d   Ivanoiu, Adrian ^a   De Volder, Anne ^b   Michel, Christian ^b   Bol, Anne ^b   Verellen, Christine ^c   Seron, Xavier ^b   Duprez, Thierry ^c   Laterre, E Christian ^a  

^a Department of Neurology ^*  (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^d VCB Pharma   (Belgium)

Author keywords

Alzheimer's disease; Anticholinesterase agent; Cholinergic neurotransmission; Physostigmine; Positron emission tomography

Indexed keywords

CHOLINE ACETYLTRANSFERASE; CHOLINESTERASE INHIBITOR; PHYSOSTIGMINE; PLACEBO;

ADULT; ALZHEIMER DISEASE; ARTICLE; BRAIN METABOLISM; CHOLINERGIC TRANSMISSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GLUCOSE BRAIN LEVEL; GLUCOSE INTAKE; GLUCOSE METABOLISM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUROPSYCHOLOGICAL TEST; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

AGED; ALZHEIMER DISEASE; APOLIPOPROTEINS E; ATTENTION; BRAIN CHEMISTRY; CHOLINESTERASE INHIBITORS; FEMALE; GLUCOSE; HUMANS; MALE; MEMORY; PHYSOSTIGMINE; REACTION TIME; SYMPATHETIC NERVOUS SYSTEM; SYNAPTIC TRANSMISSION; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0031940539     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050564     Document Type: Article

References (46)

1. Atack JR, Litvan I, Thal LJ, May C, Rapoport SI, Chase TN (1991) Cerebrospinal fluid acetylcholinesterase in progressive supra-nuclear palsy: reduced activity relative to normal subjects and lack of inhibition by oral physostigmine. J Neurol Neurosurg Psychiatry 54 : 832-835
2. Aubert I, Araujo DM, Cécyre D, Robitaille Y, Gauthier S, Quirion R (1992) Comparative alterations of nicotinic and muscarinic binding sites in Alzheimer's and Parkinson's diseases. J Neurochem 58 : 529-541
3. Blin J, Ray CA, Chase TN, Piercey M (1991) Regional cerebral glucose metabolism compared in rodents and humans. Brain Res 568 : 215-222
4. Blin J, Piercey MF, Giuffra ME, Mouradian MM, Chase TN (1994) Metabolic effects of scopolamine and physostigmine in human brain measured by positron emission tomography. J Neurol Sci 123 : 44-51
5. Blin J, Mazetti P, Mazoyer B, Rivaud S, Ben Ayed S, Malapani C, Pillon B, Agid Y (1995) Does the enhancement of cholinergic neurotransmission influence brain glucose kinetics and clinical symptomatology in progressive supranuclear palsy? Brain 118 : 1485-1495
6. Blin J, Ivanoiu A, Coppens A, De Volder A, Labar D, Michel C, Laterre EC (1997) Cholinergic neurotransmission has a different effect on cerebral glucose consumption and blood flow in young normals, aged normals and Alzheimer's disease. Neuroimage (in press)
7. Blokland A (1995) Acetylcholine: a neurotransmitter for learning and memory? Brain Res Rev 21 : 285-300
8. Callaway E, Halliday R, Naylor H (1992) Cholinergic activity and constraints on information processing. Biol Psychol 33 : 1-22
9. Content A, Mousty P, Radeau M (1990) Brulex: une base de don-nées lexicales informatisée pour le français écrit et parlé. L'Année Psychologique 90 : 551-566
10. Coppens A, Sibomana M, Bol A, Michel C (1993) MEDIMAN. an object oriented approach for medical image analysis. IEEE Trans Nucl Sci 40 : 950-955
11. Davis KL, Mohs RC (1982) Enhancement of memory processes in Alzheimer' disease with multiple-dose intravenous physostigmine. Am J Psychiatry 139 : 1421-1424
12. Davis KL, Thal LJ, Gamzu ER, Davis CS, Woolson RF, Gracon SI, Drachman DA, Schneider LS, Whitehouse PJ, Hoover TM, Morris JC, Kawas CH, Knopman DS, Earl NL, Kumar V, Doody RS (1992) A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer' disease the Tacrine collaborative study. N Engl J Med 327 : 1253-1259
13. Dubois B, Pillon B, Lhermitte F, Agid Y (1990) Cholinergic deficiency and frontal dysfunction in Parkinson's disease. Ann Neurol 28 : 117-121
14. Dunne MP, Hartley LR (1986) Scopolamine and the control of attention in humans. Psychopharmacology 89 : 94-97
15. 3H]nicotine binding in human cerebral cortex: comparison between Alzheimer' disease and the normal. J Neurochem 47 : 1948-1954
16. Flynn DD, Weinstein DA, Mash DC (1991) Loss of high-affinity agonist binding to M1 muscarinic receptors in Alzheimer' disease: implications for the failure of cholinergic replacement therapies. Ann Neurol 29 : 256-262
17. Frackowiak RSJ (1994) Functional mapping of verbal memory and language. Trends Neurol Sci 17 : 109-115
18. Francis PT, Palmer AM, Sims NR, Bowen DM, Davison AN, Esiri MM, Neary D, Snowden JS, Wilcock GK (1985) Neurochemical studies of early-onset Alzheimer' disease: possible influence on treatment. N Engl J Med 313 : 7-11
19. Geula C, Mesulam M-M (1994) Cholinergic systems and related neuropathological predilection patterns in AD. In: Terry RD, Katzman R, Bick KL (eds) Alzheimer's disease. Raven Press, New York, pp 263-291
20. Gomez-Isla T, West H, Rebeck G, Harr SD, Growdon JH, Locascio JJ, Perls TT, Lipsitz LA, Hyman BT (1996) Clinical and neuropathological correlates of apolipoprotein E ε4 in Alzheimer' disease. Ann Neurol 39 : 62-70
21. Hallak M, Giacobini E (1987) A comparison of the effects of two inhibitors on brain cholinesterase. Neuropharmacology 26 : 521-530
22. Harnacher K, Coenen I-IH, Stiicklin G (1986) Efficient stereospecific synthesis of no-carrier-added 2-[F-18]-fluoro-2deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 27 : 235-238
23. Kandel ER, Siegelbaum S (1985) Principles underlying electrical and chemical synaptic transmission. In: Kandel ER, Schwartz JH (eds) Principles of neural science. Elsevier, New York, pp 89-107
24. Lawrence AD, Sahakian BJ (1995) Alzheimer disease attention and the cholinergic system. Alz Dis Assoc Disord 9[Suppl 2] : 43-49
25. Lezak MD (1995) Neuropsychological assessment. Oxford University Press, New York
26. London ED, Broussolle EPM, Links JM, Wong DF, Cascella NG, Dannals RF, Sano M, Herning R, Snyder FR, Rippetoe LR, Toung TJK, Jaffe JH, Wagner HN (1990) Morphine-induced metabolic changes in human brain Studies with positron emission tomography and fluorine 18-fluorodeoxyglucose. Arch Gen Psychiatry 47 : 73-81
27. Mahley RW (1988) Apolipoprotein E: cholesterol transport protein with expanding role in the cell biology. Science 240 : 622-630
28. Milner B (1971) Interhemispheric differences in the localisation of psychological processes in man. Br Med Bull 27 : 272-277
29. Morris JC, Mohs RC, Rogers H, Fillenbaum G, Heyman A (1988) Consortium to Establish a Registry for Alzheimer' disease (CERAD) clinical and neuropsychological assessment of AD. Psychopharmacol Bull 24 : 641-644
30. Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G, Mellits ED, Clark C, and the CERAD investigators (1989) The Consortium to Establish a Registry for Alzheimer' disease (CERAD). Part I clinical and neurops chological assessment of Alzheimer' disease. Neurology 39 : 1159 1165
31. Morris RG, Baddeley AD (1988) Primary and working memory functionning in Alzheimer-type dementia. J Clin Exp Neuropsyiatr 10 : 279-296
32. Ordovas JM, Litwack-Klein L, Wilson PWF, et al. (1987) Apolipoprotein E isoform phenotyping methodology and population frequency with identification of apoE1 and apoE5 isoforms. J Lipid Res 28 : 371-380
33. Pappata S, Tavitian B, Traykov L, Jobert A, Dalger A, Mangin JF, Crouzel C, Digiamberardino L (1996) In vivo imaging of human cerebral acetylcholinesterase. J Neurochem 67 : 876-879
34. Perry EK, Tomlinson BE, Blessed G, Bergmann K, Gibson PH, Perry RH (1978) Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J 2 : 1457-1459
35. Phelps ME, Huang SC, Hoffmann EJ, Selin C, Sokoloff L, Kuhl DE (1979) Tomographic measurement of local cerebral glucose metabolic rate in humans with [F-18]2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol 6 : 371-388
36. Pietrzyk U, Herholz K, Fink G, Jacobs A, Mielke R, Slansky I, Würker M, Heiss WD (1994) An interactive technique for three-dimensional image registration: validation for PET, SPECT, MRI and CT brain studies. J Nucl Med 35 : 2011-2018
37. Robillard A, Demers P (1987) French version of the CERAD. Hôpital Maissonneuve-Rosemont, Montréal
38. Roses AD (1995) Apolipoprotein E genotyping in the differential diagnosis, not prediction, of Alzheimer' disease. Ann Neurol 38 : 6-14
39. Sahakian BJ (1988) Cholinergic drugs and human cognitive performance In: Iversen LL, Iversen SD, Snyder SH (eds) Handbook of psychopharmacology, vol 20. Plenum Press, New York, pp 393-424
40. Sahakian BJ, Coull JT (1994) Nicotine and tetrahydroaminoacradine - evidence for improved attention in patients with dementia of the Alzheimer type. Drug Dev Res 31 : 80-88
41. Saint-Cyr JA, Taylor AE, Nicholson K (1995) Behavior and the basal ganglia. Adv Neurol 65 : 1-28
42. Shallice T, Fletcher P, Frith CD, Grasby P, Frackowiak RSJ, Dolan RJ (1994) Brain regions associated with acquisition and retrieval of verbal episodic memory. Nature 368 : 633-635
43. Sokoloff L (1977) Relation between physiological function and energy metabolism in the central nervous system. J Neurochem 29 : 13-26
44. Spinnler H, Tognoni G (1987) Standardizzazzione e taratura italiana di test neuropsicologici. Ital J Neurol Sci 8[Suppl] : 1-120
45. Tulving E, Colotla VA (1970) Free recall of trilingual lists. Cogn Psychol 1 : 86-98
46. Wienhard K, Dahlbom M, Eriksson L, Michel Ch, Pietrzyk U, Heiss W-D (1993) Comparative performance evaluation of the ECAT EXACT and ECAT EXACT HR positron cameras. Ann Nucl Med 7[Suppl] : S68-S69